Evaluating the effect of sildenafil on the treatment of severe asthma

The effect of sildenafil on improvement of lung function and asthma attacks in patients with severe asthma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140518017738N2

Enrollment

Registered

2019-04-08

Start date

2018-09-23

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group: This group received a single 50 mg dose of oral sildenafil (made in Ahvaz pharmacy faculty) daily during one month. Intervention 2: Control group: This group receiv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with severe asthma

Exclusion criteria

Exclusion criteria: Mild to moderate severity Using immunosuppressive drug and corticosteroid ( greater than 5 mg dose) outside the study protocol in three months ago Prohibition of phosphodiesterase inhibitors Nitrate consumption Pregnancy Advanced liver failure (liver cirrhosis) Advanced renal failure (CKD stage 4,5) Having any untreated disease such as reflux, sinusitis or allergic bronchopulmonary aspergillosis (ABPA) based on history and paraclinical tests which trigger asthma exacerbation continuously Uncontrolled hypertension

Design outcomes

Primary

Measure	Time frame
Lung Volume (Forced expiratory volume in one second); (FEV1). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Lung Volume (Forced Vital Capacity); (FVC). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Lung Volume (Forced Expiratory flow 25_75%); (FEF 25-75%). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Quality of life score (upon quality of life questionnaire in asthmatic patients). Timepoint: In the first referral and one month later. Method of measurement: Questionnaire.;Walking distance upon 6 minute walking distance test (meter). Timepoint: In the first referral and one month later. Method of measurement: Six minute walking distance test.	—

Measure

Time frame

Lung Volume (Forced expiratory volume in one second); (FEV1). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Lung Volume (Forced Vital Capacity); (FVC). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Lung Volume (Forced Expiratory flow 25_75%); (FEF 25-75%). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC). Timepoint: In the first referral and one month later. Method of measurement: spirometry.;Quality of life score (upon quality of life questionnaire in asthmatic patients). Timepoint: In the first referral and one month later. Method of measurement: Questionnaire.;Walking distance upon 6 minute walking distance test (meter). Timepoint: In the first referral and one month later. Method of measurement: Six minute walking distance test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Dargahi Male Amir

Ahvaz University of Medical Sciences

dr_mehrdad_dargahi@yahoo.com+98 61 3221 5574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026